Northfield Laboratories Completes Enrollment In Pivotal Phase III PolyHeme(R) Trial; Top-line Data From Study Expected In Fall

EVANSTON, Ill.--(BUSINESS WIRE)--July 31, 2006--Northfield Laboratories Inc. (NASDAQ: NFLD) announced today that patient enrollment is complete in its pivotal Phase III trauma study with PolyHeme(R), the Company’s human hemoglobin-based oxygen-carrying red blood cell substitute.